KLRS Kalaris Therapeutics reports positive th103 phase 1a sad results from expanded neovascular amd cohorts Kalaris Therapeutics - no intrao
KLRS Kalaris Therapeutics reports positive th103 phase 1a sad results from expanded neovascular amd cohorts Kalaris Therapeutics - no intraocular inflammation observed at 2.5 mg dose after process adjustments - Enrolling phase 1B/2 th103 study; initial data expected 1h 2027
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.